Objective      To prepare a novel biological composite material

bromfenac sodium/chitosan nanoparticle loaded fibrin-binding amniotic membrane (BF/CS-FBAM)

with double sustained-released function

and investigate the drug release

in vitro

and its effect on rabbit corneal neovascularization (CNV).       Methods      The ionotro

pic gelation was used to produce bromfenac sodium/chitosan nanoparticles (BF/CS). After its physic properties were identified

the BF/CS nanoparticles were mixed with fibrin glue (FG)

and then sprayed to the surface of amniotic membrane (AM). After BF/CS-FBAM was obtained

the morphological changes and drug release

in vitro

were observed and measured. The effect of BF/CS-FBAM for CNV was observed in rabbit corneal alkali burn model

meanwhile the expression of vascular endothelial growth factor (VEGF) in the cornea were quantified by reverse transcription-quantitative PCR (RT-qPCR).       Results      The nanoparticles were smooth and spherical

in a diameter of 548.7±14.4 nm

and had a positive zeta potential of 29.8±2.2 mV. The encapsulation efficiency and loading capacity of BF/CS nanoparticles were (67.11±4.56)% and (57.71±5.38)% respectively. The nanoparticle-loaded fibrin gel was firmly adhered to the AM. Moreover

nanoparticles were coated within FBAM symmetrically

and its surface had a netted structure. The BF released from the BF/CS-FBAM was sustained for approximately 14 d

in vitro

. In rabbit corneal alkali burn model

BF/CS-FBAM group and BF/CS group had better curative effect in attenuating inflammatory reaction

anti-CNV and down-regulating VEGF than control group in every time point after injury (

P

<

0.05). Meanwhile

the expression of VEGF in BF/CS-FBAM group was significantly lower than BF/CS group in the 14th and 21st day after injury (

P

<

0.05).       Conclusion      As a novel biological implantable material

the fabricated BF/CS-FBAM locally releases BF in a sustained way and inhibits the generation of CNV.